MX2014001190A - Solucion inyectable de al menos insulina basal. - Google Patents
Solucion inyectable de al menos insulina basal.Info
- Publication number
- MX2014001190A MX2014001190A MX2014001190A MX2014001190A MX2014001190A MX 2014001190 A MX2014001190 A MX 2014001190A MX 2014001190 A MX2014001190 A MX 2014001190A MX 2014001190 A MX2014001190 A MX 2014001190A MX 2014001190 A MX2014001190 A MX 2014001190A
- Authority
- MX
- Mexico
- Prior art keywords
- type
- basal insulin
- radicals
- injectable solution
- cooh
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/721—Dextrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención se refiere a una solución inyectable que tiene un pH de 7, y que incluye al menos un tipo de insulina basal, el pI de la cual está entre 5.8 y 8.5. La invención se refiere a una composición en la forma de una solución acuosa inyectable, el pH de la cual está entre 6.0 y 8.0, incluyendo al menos: a) un tipo de insulina basal, el punto isoeléctrico (pI) de la cual está entre 5.8 y 8.5; y b) un dextrano substituido con radicales que tienen portadores de carboxilato y radicales hidrofóbicos de las fórmulas I o II, en donde R es -OH o es seleccionado del grupo que consiste de los radicales o-(f-[A]-COOH), o-(g-[B]-k-[D])m, D que comprende al menos una cadena de alquilo que comprende al menos 8 átomos de carbono, en donde R es -OH o un radical -(f-[A]-COOH)n, y R' se selecciona del grupo que consiste de los radicales o-CH2NH- [E] (-o- [F] )t y o-C(O)NH- [E] - (o- [F])t.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161522031P | 2011-08-10 | 2011-08-10 | |
FR1157291A FR2978918B1 (fr) | 2011-08-10 | 2011-08-10 | Solution injectable a ph7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 |
US201161579966P | 2011-12-23 | 2011-12-23 | |
FR1162445A FR2984749A1 (fr) | 2011-12-23 | 2011-12-23 | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 en combinaison avec une hormone gastro-intestinale a visee therapeutique |
PCT/FR2012/051880 WO2013021143A1 (fr) | 2011-08-10 | 2012-08-09 | Solution injectable d'au moins une insuline basale |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2014001190A true MX2014001190A (es) | 2014-05-12 |
Family
ID=47667929
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014001190A MX2014001190A (es) | 2011-08-10 | 2012-08-09 | Solucion inyectable de al menos insulina basal. |
Country Status (14)
Country | Link |
---|---|
US (3) | US9089476B2 (es) |
EP (2) | EP3053590A1 (es) |
JP (1) | JP5950477B2 (es) |
KR (1) | KR101810055B1 (es) |
CN (1) | CN103889442B (es) |
AU (1) | AU2012293463B2 (es) |
BR (1) | BR112014002986A2 (es) |
CA (1) | CA2843586A1 (es) |
DK (1) | DK2741765T3 (es) |
IL (1) | IL230611A (es) |
MX (1) | MX2014001190A (es) |
RU (1) | RU2578460C2 (es) |
WO (1) | WO2013021143A1 (es) |
ZA (1) | ZA201400773B (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2014001190A (es) | 2011-08-10 | 2014-05-12 | Adocia | Solucion inyectable de al menos insulina basal. |
CN107583039A (zh) | 2012-01-09 | 2018-01-16 | 阿道恰公司 | Ph为7且至少含pi为5.8至8.5之基础胰岛素和取代共聚(氨基酸)的可注射溶液 |
US20150314003A2 (en) | 2012-08-09 | 2015-11-05 | Adocia | Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
FR3001895B1 (fr) * | 2013-02-12 | 2015-07-03 | Adocia | Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes |
PL2919804T3 (pl) | 2012-11-13 | 2018-07-31 | Adocia | Szybko działająca formulacja insuliny zawierająca podstawiony związek anionowy |
JP2016503771A (ja) | 2012-12-21 | 2016-02-08 | サノフイ | エキセンジン−4誘導体 |
WO2015044922A1 (en) | 2013-09-30 | 2015-04-02 | Wockhardt Limited | Pharmaceutical composition |
EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽-4(exendin-4)胜肽類似物 |
EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
FR3020952B1 (fr) * | 2014-05-14 | 2017-09-08 | Adocia | Formulation a action rapide d'insuline comprenant un compose anionique substitue et un compose polyanionique |
US9795678B2 (en) * | 2014-05-14 | 2017-10-24 | Adocia | Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound |
FR3020947B1 (fr) | 2014-05-14 | 2018-08-31 | Adocia | Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
EP3344231B1 (en) * | 2015-09-04 | 2022-04-13 | Latitude Pharmaceuticals, Inc. | Stabilized glucagon solutions |
FR3043557B1 (fr) | 2015-11-16 | 2019-05-31 | Adocia | Composition a action rapide d'insuline comprenant un citrate substitue |
WO2017084696A1 (fr) * | 2015-11-16 | 2017-05-26 | Adocia | Composition a action rapide d'insuline comprenant un compose anionique substitue et un compose polyanionique |
WO2017145104A1 (en) * | 2016-02-25 | 2017-08-31 | Wockhardt Limited | Pharmaceutical composition of insulin glargine and amino acids |
GB201607918D0 (en) | 2016-05-06 | 2016-06-22 | Arecor Ltd | Novel formulations |
FR3052072A1 (fr) | 2016-06-07 | 2017-12-08 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
EP3562500B1 (fr) * | 2016-12-27 | 2023-07-19 | Adocia | Compositions sous forme de solution aqueuse injectable comprenant de l'amyline, un agoniste au récepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide |
FR3070264A1 (fr) | 2017-08-24 | 2019-03-01 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris de 5,8 a 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
FR3083088B1 (fr) | 2018-06-29 | 2020-10-02 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
FR3083089A1 (fr) | 2018-06-29 | 2020-01-03 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
WO2019110625A1 (fr) | 2017-12-06 | 2019-06-13 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
JP2021505605A (ja) | 2017-12-07 | 2021-02-18 | アドシア | 5.8〜8.5のpIを有する少なくとも1つの基礎インスリン、および、カルボキシレート電荷および疎水性ラジカルを有するコポリアミノ酸を含むpH7を有する注射溶液 |
WO2019110773A1 (fr) | 2017-12-07 | 2019-06-13 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
EP3740229A1 (fr) | 2017-12-07 | 2020-11-25 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
WO2019193351A1 (en) * | 2018-04-04 | 2019-10-10 | Arecor Limited | Medical infusion pump system for the delivery of an insulin compound |
WO2019193349A1 (en) * | 2018-04-04 | 2019-10-10 | Arecor Limited | Medical infusion pump system for the delivery of an insulin compound |
EP3773474A1 (en) * | 2018-04-04 | 2021-02-17 | Arecor Limited | Medical infusion pump system for the delivery of an insulin compound |
JP2021528474A (ja) * | 2018-06-29 | 2021-10-21 | ビーエイエスエフ・ソシエタス・エウロパエアBasf Se | エステルアミン塩 |
FR3083700B1 (fr) * | 2018-07-13 | 2021-03-12 | Adocia | Formulation thermostable d'insuline humaine a21g |
US20200179489A1 (en) | 2018-12-07 | 2020-06-11 | Adocia | Injectable solution at ph 7 comprising at least one basal insulin which pi is from 5.8 to 8.5 and a co-polyamino-acid bearing carboxylate charges and hydrophobic radicals and a limited amount of m-cresol |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2387201A (en) | 1942-01-12 | 1945-10-16 | Bonneville Ltd | Mono-acyl ethylene diamines |
DE3482551D1 (de) | 1983-10-26 | 1990-07-26 | Kanebo Ltd | Proteinhaltiges emulgiermittel, dessen herstellung und dieses enthaltende emulgierte kosmetische zusammensetzung. |
DE3837825A1 (de) | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
DE60043188D1 (de) | 1999-04-09 | 2009-12-03 | Amag Pharmaceuticals Inc | Hitzebeständige umhüllte kolloidale eisenoxide |
FR2801226B1 (fr) | 1999-11-23 | 2002-01-25 | Flamel Tech Sa | Suspension colloidale de particules submicroniques de vectorisation de principes actifs et son mode de preparation |
IL140844A0 (en) | 2001-01-10 | 2002-02-10 | Polygene Ltd | Cationic polysaccharide compositions |
WO2003053339A2 (en) | 2001-12-20 | 2003-07-03 | Eli Lilly And Company | Insulin molecule having protracted time action |
FR2840614B1 (fr) | 2002-06-07 | 2004-08-27 | Flamel Tech Sa | Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques |
DE10227232A1 (de) * | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
CA2508751A1 (fr) | 2002-12-04 | 2004-07-22 | Flamel Technologies | Polyaminoacides fonctionnalises par au moins un groupement (oligo)aminoacide et leurs applications notamment therapeutiques |
KR20050121748A (ko) | 2003-04-29 | 2005-12-27 | 일라이 릴리 앤드 캄파니 | 연장된 시간 작용을 갖는 인슐린 유사체 |
KR101243648B1 (ko) * | 2003-11-20 | 2013-03-14 | 노보 노르디스크 에이/에스 | 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제 |
FR2862536B1 (fr) | 2003-11-21 | 2007-11-23 | Flamel Tech Sa | Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques |
FR2873040B1 (fr) | 2004-07-19 | 2007-11-30 | Flamel Technologies Sa | Formulation colloidale d'insuline longue action et sa preparation |
JP5248113B2 (ja) | 2004-11-12 | 2013-07-31 | ノヴォ ノルディスク アー/エス | ペプチドの安定な処方 |
JP2008528509A (ja) | 2005-01-21 | 2008-07-31 | アルザ コーポレイション | 少なくとも1つの対イオンを含む、向上した安定性でマイクロニードルをコーティングするための治療用ペプチド製剤 |
WO2007116143A1 (fr) | 2006-04-07 | 2007-10-18 | Adocia | Polysaccharides bifonctionnalises |
AU2007238114B2 (en) | 2006-04-12 | 2010-10-14 | Biodel, Inc. | Rapid acting and long acting insulin combination formulations |
FR2902007B1 (fr) | 2006-06-09 | 2012-01-13 | Flamel Tech Sa | Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s) ainsi que leurs applications notamment therapeutiques |
US8679540B2 (en) | 2006-06-09 | 2014-03-25 | Flamel Technologies | Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications |
AU2007293774C1 (en) | 2006-09-07 | 2014-12-18 | Albert Einstein College Of Medicine, Inc. | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases |
FR2915683B1 (fr) | 2007-05-03 | 2009-08-07 | Flamel Technologies Sa | Formulations pharmaceutiques auto-precipitantes pour la liberation modifiee de principe actif |
FR2919188B1 (fr) | 2007-07-27 | 2010-02-26 | Proteins & Peptides Man | Complexes entre un polymere amphiphile et une proteine osteogenique appartenant a la famille des bmps |
CN101778862B (zh) | 2007-08-13 | 2014-12-17 | 诺沃-诺迪斯克有限公司 | 快速作用的胰岛素类似物 |
MX2010005245A (es) | 2007-11-16 | 2010-06-01 | Novo Nordisk As | Composiciones farmaceuticas que comprenden peptidos glp-1 o exendin-4 y un peptido de insulina basal. |
TWI394580B (zh) * | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
TWI451876B (zh) * | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
US20100069292A1 (en) * | 2008-09-02 | 2010-03-18 | Biodel, Inc. | Insulin with a basal release profile |
FR2940802A1 (fr) * | 2008-10-10 | 2010-07-09 | Adocia | Complexe entre l'insuline humaine et un polymere amphiphile et utilisation de ce complexe pour la preparation d'une formulation d'insuline humaine rapide. |
US20100167984A1 (en) | 2008-09-26 | 2010-07-01 | Adocia | Complex between human insulin and an amphiphilic polymer and use of this complex in the preparation of a fast-acting human insulin formulation |
FR2936800B1 (fr) * | 2008-10-06 | 2010-12-31 | Adocia | Polysaccharide comportant des groupes fonctionnels carboxyles substitues par un derive d'alcool hydrophobe |
US8426382B2 (en) * | 2008-10-06 | 2013-04-23 | Adocia | Polysaccharides comprising carboxyl functional groups substituted by a hydrophobic alcohol derivative |
US8759322B2 (en) | 2008-11-05 | 2014-06-24 | National University Corporation Tokyo Medical And Dental University | Hyaluronic acid derivative and pharmaceutical composition thereof |
TW201019969A (en) | 2008-11-17 | 2010-06-01 | Enzon Pharmaceuticals Inc | Branched cationic lipids for nucleic acids delivery system |
FR2948573B1 (fr) * | 2009-07-31 | 2011-11-18 | Adocia | Nouvelle forme d'administration de complexes de proteines osteogeniques |
FR2944448B1 (fr) * | 2008-12-23 | 2012-01-13 | Adocia | Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes. |
JP2012515161A (ja) * | 2009-01-13 | 2012-07-05 | ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ | 負荷電ポリマーによる生体分子の沈殿 |
US9060927B2 (en) * | 2009-03-03 | 2015-06-23 | Biodel Inc. | Insulin formulations for rapid uptake |
FR2943538B1 (fr) * | 2009-03-27 | 2011-05-20 | Adocia | Formulation a action rapide d'insuline recombinante humaine |
US9018190B2 (en) | 2009-03-27 | 2015-04-28 | Adocia | Functionalized oligosaccharides |
FR2956116A1 (fr) * | 2010-02-09 | 2011-08-12 | Adocia | Complexes polysaccharide/bmp-7 solubles a ph physiologique |
FR2958646B1 (fr) | 2010-04-07 | 2012-05-18 | Adocia | Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive d'acide hydrophobe. |
BR112012019580A2 (pt) | 2010-02-09 | 2020-08-18 | Adocia | "polissacarídeos antônicos funcionalizados por pelo menos dois grupos hidrofóbicos carreados por pelo menos um espaçador trivalente |
FR2958647B1 (fr) | 2010-04-08 | 2013-08-23 | Adocia | Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive hydrophobe porte par un spacer au moins trivalent. |
EP2388723A1 (en) | 2010-05-18 | 2011-11-23 | University College Cork-National University of Ireland, Cork | Method of assessing allergic status in a subject |
AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
EP2389945A1 (en) | 2010-05-28 | 2011-11-30 | Sanofi-Aventis Deutschland GmbH | Pharmaceutical composition comprising AVE0010 and insulin glargine |
WO2012153071A2 (fr) | 2011-05-10 | 2012-11-15 | Adocia | Polysaccharides à degré de fonctionnalisation modulable |
EP2828297A1 (fr) | 2011-05-10 | 2015-01-28 | Adocia | Oligosaccharides fonctionnalisés |
MX2014001190A (es) | 2011-08-10 | 2014-05-12 | Adocia | Solucion inyectable de al menos insulina basal. |
CN107583039A (zh) | 2012-01-09 | 2018-01-16 | 阿道恰公司 | Ph为7且至少含pi为5.8至8.5之基础胰岛素和取代共聚(氨基酸)的可注射溶液 |
FR2985429B1 (fr) | 2012-01-09 | 2016-07-29 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue obtenu par un procede de polymerisation controle |
FR2985428B1 (fr) | 2012-01-09 | 2016-05-27 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue |
CA2902256A1 (en) | 2012-02-17 | 2013-08-22 | Massachusetts Institute Of Technology | Self-regulated peptide hydrogel for insulin delivery |
PL2919804T3 (pl) | 2012-11-13 | 2018-07-31 | Adocia | Szybko działająca formulacja insuliny zawierająca podstawiony związek anionowy |
SG10202112306UA (en) | 2012-11-13 | 2021-12-30 | Adocia | Substituted anionic compounds consisting of a backbone consisting of a discrete number of saccharide units |
-
2012
- 2012-08-09 MX MX2014001190A patent/MX2014001190A/es active IP Right Grant
- 2012-08-09 DK DK12758562.8T patent/DK2741765T3/en active
- 2012-08-09 AU AU2012293463A patent/AU2012293463B2/en not_active Ceased
- 2012-08-09 EP EP16162474.7A patent/EP3053590A1/fr not_active Withdrawn
- 2012-08-09 JP JP2014524435A patent/JP5950477B2/ja not_active Expired - Fee Related
- 2012-08-09 CN CN201280038926.9A patent/CN103889442B/zh not_active Expired - Fee Related
- 2012-08-09 EP EP12758562.8A patent/EP2741765B9/fr not_active Not-in-force
- 2012-08-09 US US13/571,026 patent/US9089476B2/en not_active Expired - Fee Related
- 2012-08-09 WO PCT/FR2012/051880 patent/WO2013021143A1/fr active Application Filing
- 2012-08-09 CA CA2843586A patent/CA2843586A1/fr not_active Abandoned
- 2012-08-09 RU RU2014108829/15A patent/RU2578460C2/ru not_active IP Right Cessation
- 2012-08-09 KR KR1020147005655A patent/KR101810055B1/ko active IP Right Grant
- 2012-08-09 BR BR112014002986A patent/BR112014002986A2/pt active Search and Examination
-
2014
- 2014-01-23 IL IL230611A patent/IL230611A/en not_active IP Right Cessation
- 2014-01-31 ZA ZA2014/00773A patent/ZA201400773B/en unknown
-
2015
- 2015-05-26 US US14/721,889 patent/US20170182131A9/en not_active Abandoned
-
2018
- 2018-07-02 US US16/025,832 patent/US20180311316A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2012293463A1 (en) | 2014-03-06 |
US20180311316A1 (en) | 2018-11-01 |
CA2843586A1 (fr) | 2013-02-14 |
KR101810055B1 (ko) | 2017-12-18 |
DK2741765T3 (en) | 2016-06-13 |
US20130065826A1 (en) | 2013-03-14 |
US20150250858A1 (en) | 2015-09-10 |
EP2741765A1 (fr) | 2014-06-18 |
WO2013021143A1 (fr) | 2013-02-14 |
KR20140051384A (ko) | 2014-04-30 |
CN103889442A (zh) | 2014-06-25 |
BR112014002986A2 (pt) | 2017-06-13 |
EP2741765B9 (fr) | 2016-09-28 |
US20170182131A9 (en) | 2017-06-29 |
IL230611A0 (en) | 2014-03-31 |
US9089476B2 (en) | 2015-07-28 |
IL230611A (en) | 2016-10-31 |
AU2012293463B2 (en) | 2016-08-04 |
CN103889442B (zh) | 2016-12-28 |
JP2014521716A (ja) | 2014-08-28 |
RU2578460C2 (ru) | 2016-03-27 |
EP2741765B1 (fr) | 2016-03-30 |
ZA201400773B (en) | 2016-11-30 |
RU2014108829A (ru) | 2015-09-20 |
EP3053590A1 (fr) | 2016-08-10 |
JP5950477B2 (ja) | 2016-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2014001190A (es) | Solucion inyectable de al menos insulina basal. | |
SA518400588B1 (ar) | محلول قابل للحقن عند الرقم الهيدروجيني 7يشتمل على أنسولين قاعدي واحد على (pi)الأقل تتراوح نقطة التعادل الكهربائي الخاصة به من5.8إلى8.5وحمض بولي أميني مشترك يحمل شحنات كربوكسيلات وجذور كارهة للماء | |
HK1248607A1 (zh) | Ph為7且至少含pi為5.8至8.5之基礎胰島素和取代共聚(氨基酸)的可注射溶液 | |
NZ598520A (en) | Probiotic stabilization | |
MY192981A (en) | Cyclosporine analogue molecules modified at amino acid 1 and 3 | |
MX2019004378A (es) | Edulcorante de estevia altamente soluble. | |
AU2012282543A8 (en) | Hydrophobised calcium carbonate particles | |
MX2013008883A (es) | Composicion de acido hialuronico. | |
BR112014013780A8 (pt) | transportador de seringa | |
BR112013024714A2 (pt) | poliéster obtido a partir de um ácido dicarboxílico e/ou um derivado formador de éster do mesmo e um diol, moldes produzidos a partir de um poliéster, diol, método de fabricação para um diol e método de fabricação para poliéster | |
IN2015DN01479A (es) | ||
PH12020550827A1 (en) | Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals | |
MX348831B (es) | Administración parenteral de tapentadol. | |
BR112012018674A2 (pt) | usos de pelo menos uma polietilenimina, e de uma suspensão, e, método para aumentar o ph de uma suspensão aquosa | |
PH12015501479A1 (en) | Diclofenac composition | |
BR112013030068A2 (pt) | grânulos de controle biológico estabilizados dispersíveis em água | |
TN2012000516A1 (en) | Stable ready to use injectable paracetamol formulation | |
BR112013002230A2 (pt) | marcadores de peso molecular de acetato de glatiramer | |
BR112012019920A2 (pt) | derivados de piridazina úteis como agonístas de canabinoide-2. | |
BRPI1011630B8 (pt) | paracetamol para a administração parenteral | |
BR112012002453A2 (pt) | uso de 2-amino-2-metil-1-propanol(amp),e, método para aumentar o ph de uma suspensão aquosa. | |
BR112012031053A2 (pt) | uso de 2-aminoetanol, e, método para aumentar o ph de uma suspensão aquosa. | |
BR112014014623A2 (pt) | corpo moldado em resina para revestimento eletrostático | |
EA200900836A1 (ru) | Способ получения высокочистой внутренней соли 3-карбокси-n,n,n-триметил-1-пропанаминий гидроксида | |
BR112012018427A2 (pt) | uso de composto, e, método para aumentar o ph de uma suspensão aquosa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |